SCHEMBL3013182

SCHEMBL3013182

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 6/20 0.37
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
KCNH2 Q12809 1/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GBA1 P04062 1/20 0.36
RAB9A P51151 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
MAPK1 P28482 3/20 0.36
NPC1 O15118 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007230 0.94 SMN1; SMN2 (0.38) LMNATP53MAPTTSHRNPSR1
SCHEMBL3021393 0.93 GBA1 (0.42) LMNAMAPTNPSR1GBA1RAB9A
SCHEMBL3017650 0.92 GBA1 (0.39) LMNATP53MAPTDRD2HTR2A
SCHEMBL3004586 0.92 RAB9A (0.40) LMNATP53MAPTHTR2AHTR2C
SCHEMBL3001734 0.92 SMN1; SMN2 (0.40) LMNAMAPTDRD2HTR2AHTR2C
SCHEMBL3015608 0.92 SMN1; SMN2 (0.38) LMNAMAPTNPSR1GBA1RAB9A
SCHEMBL3009991 0.91 LMNA (0.35) LMNATP53MAPTNPSR1GBA1
SCHEMBL2998218 0.90 DRD2 (0.37) LMNATP53MAPTDRD2HTR2A
SCHEMBL3023007 0.90 MEN1 (0.38) LMNATP53MAPTDRD2HTR2A
SCHEMBL3013464 0.90 GBA1 (0.35) LMNAMAPTHTR2AHTR2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885TP53 2880/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.